| GTO ID | GTC3673 |
| Trial ID |
NCT06144606
|
| Disease |
B-Cell Lymphoblastic Leukemia
|
Acute Lymphoblastic Leukemia
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KTE-X19|Tecartus|Brexucabtagene autoleucel |
| Location approved | US, EU, UK, Australia, Canada |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Phase 2 Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) |
| Year | 2023 |
| Country | United States |
| Company sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Other ID(s) | MCC-22286 |